142 related articles for article (PubMed ID: 36636712)
1. The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.
Zhao J; Hou L; Zhu N; Huang R; Su K; Lei Y; Li Y
Int J Gen Med; 2023; 16():69-76. PubMed ID: 36636712
[TBL] [Abstract][Full Text] [Related]
2. CHA
Zhao SG; Xu JJ; Tao ZH; Jin L; Liu Q; Zheng WY; Jiang LQ; Wang NF
J Int Med Res; 2019 Jun; 47(6):2533-2544. PubMed ID: 31039653
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Predictive Value of CHA
Yilmaz S; Akboga MK; Aras D; Topaloglu S
Angiology; 2018 Jan; 69(1):38-42. PubMed ID: 28345395
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents.
Kurtul A
Clin Appl Thromb Hemost; 2018 May; 24(4):589-595. PubMed ID: 28675046
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
Zeng M; Yan X; Wu W
BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
[TBL] [Abstract][Full Text] [Related]
6. Importance and usage of the CHA2DS2-VASc score in predicting acute stent thrombosis.
Ünal S; Açar B; Yayla Ç; Balci MM; Ertem A; Kara M; Maden O; Dereağzi ŞF
Coron Artery Dis; 2016 Sep; 27(6):478-82. PubMed ID: 27187546
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation.
Luo Y; Cui S; Zhang C; Huang R; Zhao J; Su K; Luo D; Li Y
Int J Gen Med; 2022; 15():1733-1742. PubMed ID: 35221713
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention.
Hou L; Su K; Zhao J; Li Y
Int J Gen Med; 2023; 16():3977-3984. PubMed ID: 37670929
[TBL] [Abstract][Full Text] [Related]
9. Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease.
Xi H; Liu J; Xu T; Li Z; Mou X; Jin Y; Xia S
Front Cardiovasc Med; 2023; 10():1117915. PubMed ID: 36970340
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
[TBL] [Abstract][Full Text] [Related]
11. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
[TBL] [Abstract][Full Text] [Related]
12. Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.
Yi M; Tang WH; Xu S; Ke X; Liu Q
Front Cardiovasc Med; 2022; 9():837330. PubMed ID: 35669469
[TBL] [Abstract][Full Text] [Related]
13. [Predictors of in-stent restenosis in coronary heart disease patients complicating with diabetes mellitus within 2 years after drug-eluting stents implantation].
Chen J; Chen Y; Tian F; Han Y; Jing J; Liu J; Wang J; Zhou S
Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jan; 42(1):14-8. PubMed ID: 24680263
[TBL] [Abstract][Full Text] [Related]
14. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
[TBL] [Abstract][Full Text] [Related]
15. Association of serum apoA-I with in-stent restenosis in coronary heart disease.
Wang X; Zhang M; Cheng J; Zhou H
BMC Cardiovasc Disord; 2022 Aug; 22(1):355. PubMed ID: 35927634
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
17. A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis.
Luo Y; Tan N; Zhao J; Li Y
Int J Gen Med; 2022; 15():2451-2461. PubMed ID: 35264881
[TBL] [Abstract][Full Text] [Related]
18. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
[TBL] [Abstract][Full Text] [Related]
19. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CHADS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Ma X; Shao Q; Dong L; Cheng Y; Lv S; Shen H; Liang J; Wang Z; Zhou Y
Medicine (Baltimore); 2020 Jul; 99(30):e21321. PubMed ID: 32791726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
